Hematological Malignancies

Hematologic Malignancies

Powering better decisions for  you and your patients

Our comprehensive hematology test menu and expertise equip you with detailed reports and deep scientific insights to provide you with the most accurate diagnoses and risk stratifications for your patients.

supporting image

Expertise You Can Trust

45+

Over forty-five board-certified hemato-pathologists and PhD Geneticists focus on our hematopathology services including results analysis reporting, and consultative support.

375,000+

With over 375,000 hematology/oncology tests performed annually, you and your patients will benefit from our streamlined processes and expertise in the analysis and reporting of a vast variety of cases

87%

Pivotal in the development of 87% of all drugs approved by the FDA in 2020, including 100% of the oncology drugs approved by the FDA.

HLA Typing

We are one of the few global labs that provide Human Leukocyte Antigen (HLA) typing and are a partner with the National Bone Marrow Program/Be
The Match to help identify bone marrow/ stem cell donors.

Supporting your patients through their continuum of care

We offer a comprehensive portfolio of tests ranging from morphology to cytogenetics to single- and multi-gene next-generation sequencing. 

Continuum of care

We use a pathway-driven approach to perform the most appropriate
tests for your patients. 

Initial TEsting

Step 01

Initial Testing

  • Bone marrow / peripheral blood morphology
  • IHC
  • Flow cyometry
  • Cytogenetics
  • IntelliGEN® Myeloid

Step 02

New Diagnosis, Treatment, Progression/Recurrence and Monitoring

  • Gene-specific molecular assays
  • FISH profiles
  • Individual FISH probes
  • Reveal® SNP Array
  • IntelliGEN® Myeloid
  • Qualitative/Quantitative PCR tests
  • clonoSEQ® assay
New Diagnosis, Treatment, Progression/Recurrence and Monitoring

Featured Tests

Sponsored Testing Programs

HLA today

HLA Today

For some patients diagnosed with a hematologic malignancy, hematopoietic cell transplantation (HCT) may be their only chance for a cure.  Human leukocyte antigen (HLA) typing with cytogenetic testing at the time of diagnosis increases the chance of patients with acute myeloid leukemia (AML) receiving HCT in early stage disease. 

Mature woman

Blueprint’s Biomarker Testing Program

No-charge KIT D816V testing for Systemic Mastocytosis provided by Labcorp Oncology for eligible patients through the sponsored testing program from Blueprint Medicines. Early biomarker testing using a non-invasive, highly sensitive, and quantitative KIT D816V test may reduce a patient’s time to diagnosis. 

Explore Our Test Menu

Our companion diagnostics can help you transform personalized medicine into patient well-being and our comprehensive menu features more than 450 single analyte and multi-marker tests to cover
every stage of cancer care.

Labcorp Lab

Meet Our Team

  • You can trust our team of hematopathology experts

    With decades of experience in hematopathology, our medical staff and laboratory professionals bring deep knowledge and wide-ranging technical expertise. Our experts are also available for consultation and follow-up queries on your patient’s report. 

    Learn More

To order a comprehensive test or for additional information, please contact us